BioSpace News Archive

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Chief Executive Officer Myron Holubiak will deliver a virtual presentation at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 11:00 AM ET.

Invisible Health Technologies (IHT), a company specializing in Mass Fever Screening Systems and other health technologies that aid businesses with their COVID-19 reopening plans, today announces their appointment as an Authorized Value Added Reseller of Omnisense Systems Sentry MK4 Mass Fever Screening System and that units are in stock and available to ship.

Post-hospitalized patients, especially recently discharged coronavirus disease 2019 (COVID-19) patients, are at higher risk for major thromboembolic events or the formation of blood clots that could lead to death

Roseman University of Health Sciences President Dr. Renee Coffman has appointed Pedro “Joe” Greer, Jr., MD as dean of the Roseman University College of Medicine.

The following quote is attributed to Steven M. Solomon, D.V.M., M.P.H., Director of the FDA’s Center for Veterinary Medicine.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced new features of mymobility with Apple Watch, creating a first-of-its-kind remote care management system.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a webcast and conference call to discuss top-line results from the Phase 3 SPIRIT 1 study of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the company’s innovative portfolio directed against RAS cancers.

Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.

Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints